WallStSmart

Inotiv Inc (NOTV)vsNatera Inc (NTRA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Natera Inc generates 393% more annual revenue ($2.50B vs $507.36M). NTRA leads profitability with a -9.1% profit margin vs -17.1%. NTRA earns a higher WallStSmart Score of 31/100 (F).

NOTV

Avoid

31

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 2.5
Piotroski: 3/9Altman Z: -1.05

NTRA

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.8
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NOTV1 strengths · Avg: 10.0/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

NTRA2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
38.8%10/10

Revenue surging 38.8% year-over-year

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

Areas to Watch

NOTV4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.79M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-74.1%2/10

ROE of -74.1% — below average capital efficiency

NTRA4 concerns · Avg: 3.3/10
Price/BookValuation
17.3x4/10

Trading at 17.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-12.8%2/10

ROE of -12.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NOTV

The strongest argument for NOTV centers on Price/Book.

Bull Case : NTRA

The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.

Bear Case : NOTV

The primary concerns for NOTV are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 6.33 is elevated, increasing financial risk.

Bear Case : NTRA

The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.

Key Dynamics to Monitor

NOTV profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.

NOTV carries more volatility with a beta of 3.77 — expect wider price swings.

NTRA is growing revenue faster at 38.8% — sustainability is the question.

NTRA generates stronger free cash flow (18M), providing more financial flexibility.

Bottom Line

NOTV scores higher overall (31/100 vs 31/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Inotiv Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. The company is headquartered in West Lafayette, Indiana.

Natera Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.

Want to dig deeper into these stocks?